These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33772699)

  • 1. Retrospective study of aflibercept in combination therapy for high-risk proliferative diabetic retinopathy and diabetic maculopathy.
    Tao Y; Jiang P; Zhao Y; Song L; Ma Y; Li Y; Wang H
    Int Ophthalmol; 2021 Jun; 41(6):2157-2165. PubMed ID: 33772699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal aflibercept partially reverses severe non-proliferative diabetic retinopathy in treatment-naïve patients.
    Tao Y; Jiang P; Liu M; Liu Y; Song L; Wang H
    J Int Med Res; 2021 Jan; 49(1):300060520985369. PubMed ID: 33499698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical efficacy of intravitreal aflibercept versus panretinal photocoagulation for best corrected visual acuity in patients with proliferative diabetic retinopathy at 52 weeks (CLARITY): a multicentre, single-blinded, randomised, controlled, phase 2b, non-inferiority trial.
    Sivaprasad S; Prevost AT; Vasconcelos JC; Riddell A; Murphy C; Kelly J; Bainbridge J; Tudor-Edwards R; Hopkins D; Hykin P;
    Lancet; 2017 Jun; 389(10085):2193-2203. PubMed ID: 28494920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ETDRS panretinal photocoagulation combined with intravitreal ranibizumab versus PASCAL panretinal photocoagulation with intravitreal ranibizumab versus intravitreal ranibizumab alone for the treatment of proliferative diabetic retinopathy.
    Barroso RMP; Messias K; Garcia DM; Cardillo JA; Scott IU; Messias A; Jorge R
    Arq Bras Oftalmol; 2020; 83(6):526-534. PubMed ID: 33470281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal Aflibercept injection with Panretinal photocoagulation versus early Vitrectomy for diabetic vitreous hemorrhage: randomized clinical trial.
    Abd Elhamid AH; Mohamed AAEA; Khattab AM
    BMC Ophthalmol; 2020 Apr; 20(1):130. PubMed ID: 32252674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Panretinal photocoagulation after or prior to intravitreal conbercept injection for diabetic macular edema: a retrospective study.
    Zhang W; Zhao G; Fan W; Zhao T
    BMC Ophthalmol; 2021 Apr; 21(1):160. PubMed ID: 33789617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHOROIDAL THICKNESS CHANGES IN PROLIFERATIVE DIABETIC RETINOPATHY TREATED WITH PANRETINAL PHOTOCOAGULATION VERSUS PANRETINAL PHOTOCOAGULATION WITH INTRAVITREAL BEVACIZUMAB.
    Roohipoor R; Sharifian E; Ghassemi F; Riazi-Esfahani M; Karkhaneh R; Fard MA; Zarei M; Modjtahedi BS; Moghimi S
    Retina; 2016 Oct; 36(10):1997-2005. PubMed ID: 27046456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes of intravitreal anti-VEGF therapy in eyes with both neovascular age-related macular degeneration and diabetic retinopathy.
    Bandello F; Corvi F; La Spina C; Benatti L; Querques L; Capuano V; Naysan J; Chen X; Sarraf D; Parodi MB; Souied E; Freund KB; Querques G
    Br J Ophthalmol; 2016 Dec; 100(12):1611-1616. PubMed ID: 26951773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized controlled trial of panretinal photocoagulation with and without intravitreal ranibizumab in treatment-naive eyes with non-high-risk proliferative diabetic retinopathy.
    Ferraz DA; Vasquez LM; Preti RC; Motta A; Sophie R; Bittencourt MG; Sepah YJ; Monteiro ML; Nguyen QD; Takahashi WY
    Retina; 2015 Feb; 35(2):280-7. PubMed ID: 25272318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of Eyes Lost to Follow-up with Proliferative Diabetic Retinopathy That Received Panretinal Photocoagulation versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Obeid A; Su D; Patel SN; Uhr JH; Borkar D; Gao X; Fineman MS; Regillo CD; Maguire JI; Garg SJ; Hsu J
    Ophthalmology; 2019 Mar; 126(3):407-413. PubMed ID: 30077614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.
    Do DV; Nguyen QD; Vitti R; Berliner AJ; Gibson A; Saroj N; Soo Y; Boyer DS
    Ophthalmology; 2016 Apr; 123(4):850-7. PubMed ID: 26832658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visual Outcomes in the Management of Diabetic Maculopathy in Central Australia.
    Kurra P; Brazionis L; Gale J; Chen K; Lake S; Robledo KP; Henderson T
    Ophthalmic Epidemiol; 2020 Aug; 27(4):265-271. PubMed ID: 32070176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of leaking perifoveal microaneurysms on resolution of diabetic macular edema treated by combination therapy using anti-vascular endothelial growth factor and short pulse focal/grid laser photocoagulation.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Hirabayashi K; Nagaoka T; Takamura Y; Sugimoto M; Murata T
    Jpn J Ophthalmol; 2017 Jan; 61(1):51-60. PubMed ID: 27730425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topographical Response of Retinal Neovascularization to Aflibercept or Panretinal Photocoagulation in Proliferative Diabetic Retinopathy: Post Hoc Analysis of the CLARITY Randomized Clinical Trial.
    Halim S; Nugawela M; Chakravarthy U; Peto T; Madhusudhan S; Lenfestey P; Hamill B; Zheng Y; Parry D; Nicholson L; Greenwood J; Sivaprasad S
    JAMA Ophthalmol; 2021 May; 139(5):501-507. PubMed ID: 33704351
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation between Diabetic Retinopathy Severity and Oxygen Metabolism in Patients with Diabetic Macular Edema during Treatment with Intravitreal Aflibercept.
    Blindbæk SL; Peto T; Grauslund J
    Ophthalmic Res; 2020; 63(2):106-113. PubMed ID: 31715608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
    Ruiz-Moreno JM
    Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal Aflibercept for Patients With Diabetic Macular Edema Refractory to Bevacizumab or Ranibizumab: Analysis of Response to Aflibercept.
    Chen YY; Chang PY; Wang JK
    Asia Pac J Ophthalmol (Phila); 2017; 6(3):250-255. PubMed ID: 28436640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Change in Diabetic Retinopathy Through 2 Years: Secondary Analysis of a Randomized Clinical Trial Comparing Aflibercept, Bevacizumab, and Ranibizumab.
    Bressler SB; Liu D; Glassman AR; Blodi BA; Castellarin AA; Jampol LM; Kaufman PL; Melia M; Singh H; Wells JA;
    JAMA Ophthalmol; 2017 Jun; 135(6):558-568. PubMed ID: 28448655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intravitreal aflibercept for diabetic macular edema.
    Korobelnik JF; Do DV; Schmidt-Erfurth U; Boyer DS; Holz FG; Heier JS; Midena E; Kaiser PK; Terasaki H; Marcus DM; Nguyen QD; Jaffe GJ; Slakter JS; Simader C; Soo Y; Schmelter T; Yancopoulos GD; Stahl N; Vitti R; Berliner AJ; Zeitz O; Metzig C; Brown DM
    Ophthalmology; 2014 Nov; 121(11):2247-54. PubMed ID: 25012934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.